Crinetics Pharmaceuticals, Inc. (CRNX)

Wie das Geld verdient wird

Revenue comes from two sources. The first is net product revenue from PALSONIFY in the United States: the company sells through a third-party logistics provider to a specialty distributor and specialty pharmacies, which in turn serve prescribers and patients; product revenue began only in the fourth quarter of 2025 and was $5.4 million for the year. The second is collaboration and license revenue, $2.3 million in 2025, essentially from the 2022 license granting Sanwa Kagaku Kenkyusho exclusive rights to paltusotine in Japan — a $13.0 million upfront plus a $1.0 million milestone booked in 2024, recognised over time as data-exchange obligations are satisfied, plus a small clinical supply agreement. Future royalties and development milestones under that license, and a veterinary license to Loyal for CRN01941, are contingent and largely unrecognised. Operating expenses are roughly seventy times revenue, so the company is funded by equity raises rather than by sales.

What protection exists rests on intangibles: patents and regulatory exclusivity around paltusotine, a molecule the company discovered in house, and the fact that PALSONIFY is the first once-daily oral somatostatin receptor ligand approved for acromegaly, against injectable incumbents. The company's own filing lists competition from other somatostatin agonist programmes as a risk and notes it has only limited experience conducting commercial activities, so the advantage is narrow and dependent on one product: with a single approved drug, no track record of repeat commercial success and no scale or cost edge, there is nothing durable beyond the intellectual property and the head start in oral dosing.

Acromegaly is a chronic disease caused by a growth-hormone-secreting tumour and is treated continuously; patients do not postpone therapy because the economy weakens, so underlying demand is defensive rather than cyclical. What drives the revenue line in practice is not the economic cycle but the launch curve: how many endocrinologists prescribe, how many patients convert from injectable somatostatin analogues to a daily pill, and how quickly payors grant coverage. Investors should expect volatility from launch dynamics, reimbursement decisions and clinical read-outs, not from GDP.

Wichtigste Risiken

• Everything depends on one product — The company states that its ability to become profitable primarily depends on the commercial success of paltusotine, approved as PALSONIFY in the U.S.; it has two other candidates in clinical development and all remaining programmes are preclinical or at the discovery stage. If it cannot commercialise PALSONIFY or develop further candidates, or is significantly delayed, it says its business will be materially harmed.
• Losses since inception and need for more capital — Crinetics reports a limited operating history and significant operating losses since inception, and says it may never become profitable or sustain profitability. It may require substantial additional financing; failure to obtain it on acceptable terms could force it to delay, limit, reduce, abandon or terminate development programmes, commercialisation efforts or other operations.
• Coverage, reimbursement and market acceptance — Commercial success depends on the degree of market acceptance by physicians, patients and payors, and on the extent to which governments and health insurers establish coverage, adequate reimbursement levels and favourable pricing. Failure to obtain or maintain adequate reimbursement could limit the company's ability to market its products and reduce its ability to generate revenue.
• Small and imprecisely known patient populations — The number of patients with the rare endocrine diseases and endocrine-related tumours the company targets is small and has not been established with precision. If the market opportunities turn out to be smaller than management believes, revenue may be adversely affected. The same scarcity makes it difficult to enrol and retain patients in clinical trials, which can delay development.
• Competition from other somatostatin agonists — The company faces competition from entities that have developed or may develop somatostatin agonist products and other competing candidates. If competitors move faster or their technologies prove more effective, Crinetics' ability to develop and commercialise its own products could be adversely affected.
• Reliance on third parties for manufacturing — Crinetics relies on third parties for raw materials, active pharmaceutical ingredients and drug product intermediates, in the U.S. and abroad, and expects to continue doing so. That reliance raises the risk of not having sufficient quantities of its products, or not at an acceptable cost or free of tariffs, which could delay or impair development and commercialisation.
• Side effects and continuing regulatory obligations — Use of the company's products and candidates could be associated with side effects or adverse events during development or commercialisation. PALSONIFY remains subject to ongoing regulatory review and could face labelling restrictions, marketing limits or withdrawal from the market, and the company could incur penalties if it fails to comply with regulatory requirements.

Die größten Kunden machen 100 % des Umsatzes aus

Two customers accounted for the whole of consolidated gross product revenue in fiscal 2025: Customer A at 58% and Customer B at 42%. These are the specialty distributor and specialty pharmacies that Crinetics sells to through a third-party logistics provider, and accounts receivable are due from them. The concentration is a distribution-channel fact rather than end-demand concentration — those customers resell into a broad range of downstream channels, and the company says it has not experienced material credit losses to date — but it does mean the receivable balance sits with very few counterparties.